Ameriprise
SLDB icon

Ameriprise’s Solid Biosciences SLDB Stock Holding History

Ameriprise’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Sell
2,225,783
-213,066
-9% -$1.62M ﹤0.01% 1465
2026
Q1 		$17.6M Buy
+2,438,849
New +$15.7M ﹤0.01% 1503
2021
Q1 		– Sell
-1,615
Closed -$183K – 3894
2020
Q4 		$183K Buy
+1,615
New +$102K ﹤0.01% 3629

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's SLDB Position: Q2 2026 in Review

Ameriprise reduced its Solid Biosciences (SLDB) stake by 8.7% in Q2 2026, selling an estimated $1.62M and leaving 2,225,783 shares worth $22.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Ameriprise first reported a position in SLDB in Q4 2020 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Ameriprise held 2,225,783 shares of Solid Biosciences worth $22.2M as of Q2 2026.
  • Ameriprise sold 213,066 Solid Biosciences shares in Q2 2026, an estimated $1.62M.
  • Solid Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1465 holding.
  • Ameriprise first reported a position in Solid Biosciences in Q4 2020 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.